Real-World Data on Empagliflozin and Dapagliflozin Use in Patients with HEART Failure: The RED–HEART Study

The RED-HEART study provided comprehensive real-world data about implementing SGLT2is in patients with HF. These results suggest that there is a need for organized action and close collaboration between healthcare providers to improve the implementation of SGLT2is, especially in patients with HF with preserved ejection fraction and chronic kidney disease.